These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 3410164

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Mechanisms of proteinuria in diabetic nephropathy. II. A study of the size-selective glomerular filtration barrier.
    Friedman S, Jones HW, Golbetz HV, Lee JA, Little HL, Myers BD.
    Diabetes; 1983 May; 32 Suppl 2():40-6. PubMed ID: 6086024
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Glomerular size- and charge selectivity in type 2 (non-insulin-dependent) diabetic patients with diabetic nephropathy.
    Gall MA, Rossing P, Kofoed-Enevoldsen A, Nielsen FS, Parving HH.
    Diabetologia; 1994 Feb; 37(2):195-201. PubMed ID: 8163055
    [Abstract] [Full Text] [Related]

  • 6. Proteinuria and functional characteristics of the glomerular barrier in diabetic nephropathy.
    Carrie BJ, Myers BD.
    Kidney Int; 1980 May; 17(5):669-76. PubMed ID: 6157049
    [Abstract] [Full Text] [Related]

  • 7. Glomerular size and charge selectivity in insulin-dependent diabetes mellitus.
    Deckert T, Feldt-Rasmussen B, Djurup R, Deckert M.
    Kidney Int; 1988 Jan; 33(1):100-6. PubMed ID: 3352157
    [Abstract] [Full Text] [Related]

  • 8. Mechanism of the antiproteinuric effect of indomethacin in nephrotic humans.
    Golbetz H, Black V, Shemesh O, Myers BD.
    Am J Physiol; 1989 Jan; 256(1 Pt 2):F44-51. PubMed ID: 2463770
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effects of cyclosporin A on glomerular barrier function in the nephrotic syndrome.
    Zietse R, Wenting GJ, Kramer P, Schalekamp MA, Weimar W.
    Clin Sci (Lond); 1992 Jun; 82(6):641-50. PubMed ID: 1320544
    [Abstract] [Full Text] [Related]

  • 15. Heteroporous model of glomerular size selectivity: application to normal and nephrotic humans.
    Deen WM, Bridges CR, Brenner BM, Myers BD.
    Am J Physiol; 1985 Sep; 249(3 Pt 2):F374-89. PubMed ID: 4037090
    [Abstract] [Full Text] [Related]

  • 16. Effect of atrial natriuretic peptide on renal and vascular permeability in diabetes mellitus.
    Zietse R, Derkx FH, Weimar W, Schalekamp MA.
    J Am Soc Nephrol; 1995 Jun; 5(12):2057-66. PubMed ID: 7579054
    [Abstract] [Full Text] [Related]

  • 17. Glomerular permeability to neutral and anionic dextrans in experimental diabetes.
    Michels LD, Davidman M, Keane WF.
    Kidney Int; 1982 May; 21(5):699-705. PubMed ID: 6180213
    [Abstract] [Full Text] [Related]

  • 18. Converting enzyme inhibition and glomerular size selectivity in diabetic nephropathy.
    Meyer TW, Morelli E, Loon N, Peters W, Myers BD.
    J Am Soc Nephrol; 1990 Nov; 1(5 Suppl 2):S64-8. PubMed ID: 16989068
    [Abstract] [Full Text] [Related]

  • 19. Glomerular permselectivity in early stages of overt diabetic nephropathy.
    Andersen S, Blouch K, Bialek J, Deckert M, Parving HH, Myers BD.
    Kidney Int; 2000 Nov; 58(5):2129-37. PubMed ID: 11044234
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.